Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00

Key Points

• Needham raised its Definium Therapeutics price target to $66 from $50 and maintained a “buy” rating, implying 52.5% upside; analysts overall have a consensus “Buy” rating and a $57 target.
• DFTX shares rose 5.8% to $43.28, though the company reported a quarterly loss of $1.44 per share versus the expected $0.55 loss. Analysts expect a full-year loss of approximately $2.65 per share.
• Positive Phase 3 results for the company’s DT120 ODT anxiety treatment supported potential regulatory submission and boosted investor sentiment, but revised earnings forecasts signal continued development spending and delayed profitability.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) had its price target upped by analysts at Needham & Company LLC from $50.00 to $66.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's price objective indicates a potential upside of 52.50% from the stock's previous close.

Other research analysts have also issued reports about the company. Canaccord Genuity Group set a $58.00 price objective on Definium Therapeutics and gave the company a "buy" rating in a research report on Tuesday, June 30th. Citigroup reaffirmed a "buy" rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an "outperform" rating in a report on Monday, June 22nd. JonesTrading boosted their price target on Definium Therapeutics from $61.00 to $74.00 and gave the stock a "buy" rating in a research report on Wednesday, June 24th. Finally, Robert W. Baird upped their price target on Definium Therapeutics from $37.00 to $57.00 and gave the stock an "outperform" rating in a report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Definium Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $57.00.

Definium Therapeutics Trading Up 5.8%

DFTX traded up $2.37 during trading on Wednesday, hitting $43.28. 6,335,414 shares of the company's stock were exchanged, compared to its average volume of 2,290,860. Definium Therapeutics has a 1 year low of $8.70 and a 1 year high of $49.70. The stock has a 50 day moving average price of $38.68 and a 200 day moving average price of $26.34. The firm has a market cap of $4.31 billion, a P/E ratio of -12.62 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, analysts expect that Definium Therapeutics will post -2.65 EPS for the current fiscal year.

Insider Activity

In other news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares of the company's stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the business's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 48,096 shares of company stock valued at $2,165,763. Corporate insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Commodore Capital LP boosted its stake in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company's stock valued at $32,450,000 after buying an additional 475,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Definium Therapeutics by 11.0% in the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company's stock worth $23,732,000 after buying an additional 198,878 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company's stock worth $36,563,000 after buying an additional 24,349 shares during the last quarter. UBS Group AG raised its holdings in Definium Therapeutics by 7.3% in the third quarter. UBS Group AG now owns 551,809 shares of the company's stock valued at $6,506,000 after acquiring an additional 37,364 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in Definium Therapeutics in the third quarter valued at $4,337,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive topline results from the Phase 3 Voyage study, saying its LSD-derived oral therapy reduced anxiety symptoms in patients with generalized anxiety disorder. This is the second positive Phase 3 trial for DT120 ODT and supports the company’s plans for potential regulatory submission. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: The favorable trial update triggered a sharp increase in trading activity and helped push DFTX closer to its 52-week high. The results may improve investor expectations for DT120’s commercial potential and future revenue growth. This LSD-Based Drug Just Scored Again. Definium Stock Soars.
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, highlighting the market significance of the update. Separately, reported short-interest data showed no shares sold short, but the figures appeared inconsistent and may have limited analytical value.
• Negative Sentiment: HC Wainwright reduced its earnings estimates across 2026–2030, including lowering its 2026 forecast to a loss of $3.05 per share from $2.10 and its 2027 forecast to a loss of $1.71 from $1.22. The revisions indicate continued heavy development spending and delay the expected earnings ramp despite the stronger clinical outlook.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source